ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a therapeutic challenge due to its immunosuppressive microenvironment. This study reveals that the SOX9/TIMP1/FAK/PI3K axis impedes dendritic cell (DC) maturation and antitumor immunity in GC, using integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST-seq) analysis. Irgd-conjugated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) co-loaded with small interfering RNA targeting SOX9 (si-SOX9), the photosensitizer chlorin e6 (Ce6), and L-arginine (L-Arg) (termed iRGD NPs@si-SOX9/CL) are developed to simultaneously disrupt this immunosuppressive axis and amplify photodynamic therapy (PDT). In vitro, these NPs enhance cellular uptake and lysosomal escape, suppressing SOX9 expression and generating reactive oxygen species (ROS) and nitric oxide (NO) upon near-infrared (NIR) irradiation. This dual action significantly inhibits GC cell proliferation, migration, and invasion while promoting DC maturation (evidenced by elevated CD80/CD86 expression) and CD8⁺ T-cell activation. In vivo, iRGD modification boosts tumor accumulation of NPs, and NP-mediated PDT synergized with SOX9 silencing to suppress tumor growth in GC xenografts. Mechanistically, NPs@si-SOX9/CL blocks SOX9-driven transcriptional activation of TIMP1, reversing FAK/PI3K signaling and restoring DC function. Consequently, tumor-infiltrating mature DCs and cytotoxic T lymphocytes increase significantly, reshaping the immunosuppressive niche. This nanoplatform offers a promising strategy to augment GC immunotherapy by precisely targeting tumor-intrinsic immunosuppression and potentiating PDT efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.